Search Within

Matthew David Hellmann

  1. "2017"
Formats
  1. Journal Article (22)
  2. Meeting Abstract (22)
Groups
  1. Department of Medicine (44)
  2. Solid Tumor Oncology Division (44)
  3. Thoracic Oncology (44)
  4. Melanoma and Immunotherapeutics Service (13)
  5. GSK Faculty (12)
  6. Department of Pathology and Laboratory Medicine (10)

More Groups

People
  1. Jamie Chaft (7)
  2. Jedd Wolchok (7)
  3. Margaret Callahan (6)
  4. Natasha Rekhtman (6)
  5. Alexandra Snyder Charen (5)
  6. Hira Rizvi (5)

More People

Years
  1. 2017 (44)
Publications
  1. Journal of Clinical Oncology (9)
  2. Annals of Oncology (6)
  3. Journal of Thoracic Oncology (3)
  4. Asia-Pacific Journal of Clinical Oncology (2)
  5. Cancer Immunology Research (2)
  6. Journal for ImmunoTherapy of Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. Oxford University Press (8)
  3. Nature Publishing Group (5)
  4. Elsevier Inc. (4)
  5. American Association for Cancer Research (3)
  6. Biomed Central Ltd (2)

More Publishers

Results (44)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Dynamics of immune-mediated thyroid dysfunction in patients with advanced renal cell carcinoma receiving checkpoint inhibitor therapy
    Meeting Abstract

    Osorio, J. C.; Patil, S.; Coskey, D. T.; Carlo, M. I.; Feldman, D. R.; Hellmann, M. D.; Voss, M. H.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma
    Meeting Abstract

    Miao, D.; Margolis, C.; Martini, D.; Mullane, S. A.; Cullen, D.; Horak, C.; Wind-Rotolo, M.; Hellmann, M. D.; Voss, M. H.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Use of PD-1 pathway inhibitors among patients with non-small cell lung cancer (NSCLC) and preexisting autoimmune disorders
    Meeting Abstract

    Leonardi, G. C.; Gainor, J. F.; Azimi, R. S.; Riess, J.; Rizvi, H.; Hellmann, M. D.; Awad, M. M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010
    Meeting Abstract

    Hellmann, M. D.; Ma, J.; Garon, E. B.; Hui, R.; Gandhi, L.; Soria, J. C.; Anderson, K. M.; Lubiniecki, G. M.; Piperdi, B.; Herbst, R. S.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients
    Meeting Abstract

    Fong, L.; Forde, P. M.; Powderly, J. D.; Goldman, J. W.; Nemunaitis, J. J.; Luke, J. J.; Hellmann, M. D.; Kummar, S.; Doebele, R. C.; Mahadevan, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors
    Meeting Abstract

    Burris, H. A.; Gordon, M. S.; Hellmann, M. D.; LoRusso, P.; Emens, L. A.; Hodi, F. S.; Lieu, C. H.; Infante, J. R.; Tsai, F. Y. C.; Eder, J. P.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gandhi, L.; Johnson, M. L.; Opyrchal, M.; Ramalingam, S.; Janne, P.; Chachoua, A.; Ordentlich, P.; Brouwer, S.; Sankoh, S.; Schmidt, E.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Clinical activity of adenosine 2A receptor (A2AR) inhibitor CPI-444 is associated with tumor expression of adenosine pathway genes and tumor immune modulation
    Meeting Abstract

    Hotson, A.; Powderly, J.; Emens, L.; Forde, P.; Hellman, M.; Fong, L.; Markman, B.; Hughes, B.; Goldman, J.; Sznol, M.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • The development of brain metastasis in the patients with metastatic non-small cell lung cancer (NSCLC) and melanoma treated with immune checkpoint inhibitors: A retrospective analysis
    Meeting Abstract

    Chaul-Barbosa, C.; Niotis, K.; Hellmann, M.; Callahan, M.; Daras, M.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save